Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00646737 |
Recruitment Status :
Completed
First Posted : March 28, 2008
Last Update Posted : February 23, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Kidney Transplantation | Drug: Mycophenolate sodium | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase IV Study of Enteric-coated Mycophenolate Sodium in Combination With Tacrolimus in Renal Transplant Patient |
Study Start Date : | May 2008 |
Actual Primary Completion Date : | December 2008 |
Actual Study Completion Date : | December 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Mycophenolate sodium
|
Drug: Mycophenolate sodium
Mycophenolate sodium |
- Gastrointestinal symptoms in renal transplant patients treated with the immunosuppression regimen of tacrolimus and mycophenolate at baseline, 8 and 16 weeks [ Time Frame: 8 and 16 weeks ]
- Impact of gastrointestinal symptoms on quality of life. Tolerability of mycophenolate sodium in combination with tacrolimus assessed by OSRS. Safety of mycophenolate sodium in combination with tacrolimus assessed by incidence of adverse events [ Time Frame: 8 and 16 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria
- Age between 18 and 65 years;
- First or second renal transplant within at least 12 weeks;
- Clinical stability, in the opinion of the investigator, during at least 8 weeks before inclusion in the study;
- Women of reproductive age must use contraceptive methods and present negative results in pregnancy test Serum creatinine < 2.5 mg/dE; Patients in use of a immunosuppression regimen based on tacrolimus and mycophenolate mofetil (generic or not, in any dose), who present gastrointestinal symptoms Capacity to complete the study requirements;
Exclusion criteria History of acute rejection,
- Proven or not by biopsy, in the last 2 months before the study;
- Recipients of multiple organs;
- Participation in any clinical investigation in the last 6 months before the present study;
- Thrombocytopenia (platelets <75,00O/mm3), leucopenia (total leukocytes <4,000/mm3)and/or anemia (hemoglobin <9.0 gldL) before inclusion in the study;
- Clinically important disease, in the opinion of the investigator, including systemic infection, within 2 weeks before inclusion in the study;
- Presence of any neoplasia, current or past, except resected basal cell carcinoma;
- Any surgical or medical condition that could significantly alter the absorption, distribution, metabolism or excretion of medicines or that could put the patient in danger as a result of participation in the study;
- History of drug or alcohol abuse within previous 12 months of inclusion in the study, Current or prior use in the last 2 months of bile acid-adsorbing resins(cholestyramine and colestipol).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00646737
Brazil | |
Novartis Investigative Site | |
Sao Paulo, Brazil |
Study Director: | Novartis | Novartis |
Responsible Party: | Novartis |
ClinicalTrials.gov Identifier: | NCT00646737 |
Other Study ID Numbers: |
CERL080ABR02 |
First Posted: | March 28, 2008 Key Record Dates |
Last Update Posted: | February 23, 2017 |
Last Verified: | February 2017 |
Kidney transplantation conversion mycophenolate mofetil mycophenolate sodium, tacrolimus |
Mycophenolic Acid Antibiotics, Antineoplastic Antineoplastic Agents Antibiotics, Antitubercular Antitubercular Agents |
Anti-Bacterial Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |